SUMMARY Dobutamine is a newly developed catecholamine reported to have minimal direct vascular effects relative to its inotropic activity and to have less chronotropic and arrhythmogenic properties than other catecholamines used in the treatment of low output states. In this study, the acute hemodynamic effects of dobutamine were compared to those of dopamine in 13 patients with chronic low output cardiac failure. At dosages adjusted to achieve similar increments in cardiac output, dobutamine reduced left yen-OF THE MANY AGENTS capable of improving cardiac output in patients with low output cardiac failure, the catecholamines are among the most widely used. As a group, these drugs exert similar direct cardiac effects mediated by stimulation of beta adrenergic receptors. Important differences in their peripheral vascular actions are found among them. At times, these vascular effects are un-tricular filling pressure (LVFP) from 25 ± 2 mm Hg (SEM) to 17 ± 2 mm Hg, while dopamine increased LVFP to 30 ± 3 mm Hg and in six patients caused arterial 02 saturation to fall below 90%. This poor response to dopamine was probably the result of its vasoconstrictive effects and illustrates the potential advantages of using a cardioselective agent such as dobutamine when the desired goal of therapy is to improve ventricular function by direct inotropic stimulation. desirable and can offset benefits gained from the inotropic actions. In addition, the catecholamines currently used for treatment of heart failure frequently cause tachycardia and/or arrhythmias. Newer agents have been developed and tested under laboratory conditions with the purpose of finding one that would retain the inotropic activity of the earlier catecholamines without direct vascular, chronotropic and arrhythmogenic actions. Of many such compounds tested, dobutamine appears to come close to fulfilling these criteria.
We' and others2 3 have previously described the acute hemodynamic effects of dobutamine in patients with severe left ventricular dysfunction. In the present study, we compared the effects of dobutamine to those of dopamine in 13 such patients. Our studies suggest that dobutamine has important advantages over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure when hypotension is not present.
Methods and Materials
The patients studied were all males, hospitalized for symptoms of chronic cardiac failure due to cardiomyopathy (8) , arteriosclerotic heart disease (4), or persisting after prosthetic aortic valve replacement (1) . Their ages ranged between 48 and 68 years, averaging 58 years. All patients had received digitalis and diuretic therapy prior to the study and none were in acute pulmonary edema or cardiogenic shock at the time of study. Two patients were in chronic atrial fibrillation and the remainder were in sinus rhythm. Prior to the study, informed consent was obtained from each patient.
On the morning of the study, the patient was brought to a specially equipped hemodynamic study unit The following considerations were important in determining the dosages used for comparing the two drugs. Since improved cardiac output is a major objective when inotropic agents are given to patients with low output cardiac failure, we thought it necessary that the two drugs be compared if possible, at dosages yielding significant and similar increases in cardiac output. In previous studies of patients with poor left ventricular function,1 we found that infusions of dobutamine in amounts of 10.7 ± 1.1 ,ug/kg/min (mean ± SEM) were well tolerated and raised cardiac index by an average of 82% (from 1.9 ± 0.2 L/min/m2 to 3.3 ± 0.2 L/min/m2). Accordingly, in the present study, we chose to study dobutamine at an infusion rate of 10 ,ug/kg/min. Since it was also important that dobutamine not always be the first agent studied, when dopamine was studied first, we gave it at more than one infusion rate (table 1) and then chose for analysis, data obtained at the dopamine infusion rate which yielded a cardiac output closest to that which was present during the 10 jig/kg/min dobutamine infusion. As can be seen, a CI obtained during infusion of dopamine agreed within 0.4 L/min/m2 of the CI present during dobutamine infusion in all but three patients.
Results
In table 2 are listed the various parameters measured during the control and drug infusion periods for each of the 13 *In five patients, a satisfactory WP could not be obtained and in these patients, the LVSWI was calculated using the PADP as a reflection of the left ventricular filling pressure (LVFP). mm Hg, and 32 ± 3 mm Hg. Each was significantly lower (P < 0.01) during dobutamine infusion than during dopamine infusion. Wedge pressure was measured in eight patients and averaged 24 + 2 mm Hg during the control period, falling to 16 ± 3 mm Hg during infusion of dobutamine. Wedge pressure increased to 28 ± 5 mm Hg during dopamine infusion, a value significantly higher (P < 0.01) than during dobutamine infusion. Right atrial pressure (12 pts) fell from 11 ± 2 mm Hg to 6 ± 2 mm Hg during dobutamine infusion and was significantly higher during dopamine infusion, averaging 12 ± 3 mm Hg.
Cardiac Index. Cardiac index prior to drug infusion was 1.9 ± 0.1 L/min/m2. During dobutamine infusion, CI increased to 2.9 ± 0.2 L/min/m2 and as expected, was not significantly different than the average of 2.7 ± 0.2 L/min/m2 achieved during dopamine infusion.
Heart Rate. Heart rate averaged 85 ± 2 beats/min during the control period and increased to a similar extent during both dobutamine and dopamine infusions averaging 100 ± 4 and 99 ± 6 beats/min respectively. Stroke Index. Stroke index was 25 ± 2 cc/beat during the control period and increased by a similar extent during infusion of dobutamine and dopamine averaging 31 ± 2 and 30 ± 3 cc/beat respectively.
Left Ventricular Stroke Work Index ( fig. 1 ). During the control period LVSWI averaged 19 dobutamine infusion and to 12 ± 1 g-m/m2 during infusion of dopamine. The difference in RVSWI between dobutamine and dopamine was not significant.
Pulmonary Arteriolar Resistance. This measurement (8 pts) fell from 5.1 ± 1.0 mm Hg/L/min to 3.9 ± 0.8 mm Hg/L/min during dobutamine infusion, which was not significantly different from the mean of 2.9 + 0.4 mm Hg/L/min present during dopamine infusion.
Oxygen Saturation. Arterial and pulmonary oxygen saturation was measured in 12 patients. During control, AO2
was 90% or above in every patient averaging 96 ± 0.4%. During dobutamine, AO2 remained above 90% in 11 patients averaging 93 ± 0.8%. During dopamine infusion, AO2 was significantly lower (P < 0.01) averaging 87 ± 2% and was below 90% in six patients. As can be seen in figure 3 , in each of these six patients, the fall in AO2 which occurred during dopamine infusion was associated with LVFP above 35 mm Hg which, in four of the six patients, was due to a large increase in LVFP, ranging from 15 to 21 mm Hg. In contrast, four of the six patients whose AO2 remained above 90% during dopamine infusion, had a fall in LVFP and in none was LVFP above 28 mm Hg. PAO2 averaged 45 ± 5% during the control period and increased during both dobutamine and dopamine infusions, averaging 64 ± 2% and 57 ± 4%, respectively. Although PAO2 was higher with dobutamine than with dopamine, the AO2 -PAO2 difference, which averaged 51 ± 5% prior to infusion of either drug, was narrowed similarly with both dobutamine and dopamine, averaging 30 ± 2% and 30 ± 3%, respectively. Adverse Effects. No serious adverse effects resulted from the study. In a few patients, shortness of breath developed during dopamine infusion, and in one patient, chest pain occurred during infusion of dopamine at a dosage of 5 ,vg/kg/min but he responded promptly to nitroglycerin and discontinuation of the infusion. Although arrhythmias were uncommon, some patients had more ventricular ectopic LEFT reported improved sodium diuresis in patients with congestive heart failure during dopamine infusion. Subsequently, dopamine has become popular for the treatment of patients with various types of shock5 and low output states.6
The popularity of dopamine is largely due to its potent inotropic activity coupled with its unique ability to selectively vasodilate vessels in splanchnic and renal vascular beds by a mechanism other than adrenergic stimulation.7 In addition, when used in moderate dosages, dopamine, although exerting both alpha-and beta-adrenergic peripheral vascular effects, seems less likely to cause either excessive vasodilatation and hypotension than isoproterenol or excessive vasoconstriction and increased cardiac work, as norepinephrine does. In spite of these theoretical advantages, the direct peripheral vascular effects of dopamine which are largely dose dependent8 may, as in the case of isoproterenol and norepinephrine, limit its usefulness under certain conditions. In order to eliminate some of these problems, Tuttle and Mills9 modified the chemical structure of isoproterenol in an attempt to develop a substance having potent inotropic activity with minimal chronotropic, arrhythmogenic, or direct peripheral vascular effects. Among several substances evaluated, dobutamine, a derivative of dopamine, appeared to best fit these requirements. Experimental studies have shown dobutamine to be a direct-acting compound with its action being independent of stored catecholamines. When compared to other catecholamines at dosages producing equivalent inotropic effects, dobutamine also appears to have less arrhythmogenic activity and to exert less effect on peripheral vascular resistance. Although both alpha-and beta-adrenergic actions on peripheral vasculature can be elicited by dobutamine during selective adrenergic blockade, these effects seem to be slight in comparison to its direct cardiac effects.10" Clinical studies have shown dobutamine to increase cardiac output in patients with and without heart failure'ẁ ithout substantially raising heart rate. Isoproterenol caused greater rate increases with comparable increases in cardiac output. '2-14 In the present study, we compared the acute hemodynamic effects of dobutamine to those of dopamine in patients with chronic low output cardiac failure. It is important to note that none of these patients were in clinical shock and perfusion pressure was considered to be adequate in all patients prior to infusion of either drug. Augmentation of cardiac output and not arterial pressure was therefore a desired therapeutic endpoint in addition to reduction in the elevated left ventricular filling pressure.
Experimentally, dobutamine and dopamine exert similar inotropic responses when given at low dosages and at a respective ratio of one to four.9 With increasing dosages of dopamine, however, its pressor effects become important. In the present study, it was not possible to measure inotropic activity per se and we therefore elected to compare the two 379 0 agents at dosages yielding similar, and in most instances, physiologically significant increases in cardiac output. Under these conditions, it becomes apparent that dobutamine would be preferred to dopamine if the desired goal in such patients is to temporarily improve ventricular function. As can be seen in figures 1 and 2, dobutamine shifted the plot of stroke work to filling pressure upward and to the left for both left and right ventricles, whereas dopamine shifted this relationship upward and to the right. This difference suggests that considerably more improvement in ventricular function occurred with dobutamine than with dopamine. Furthermore, LVFP fell in 12 of the 13 patients during dobutamine infusion (increasing by 1 mm Hg in one patient) but increased in eight of the 13 patients during dopamine infusion. In several instances, the elevated LVFP was associated with arterial hypoxemia, dyspnea, and auscultatory evidence of early pulmonary edema. These undesirable effects of dopamine occurred primarily in patients receiving infusion rates above 5 ,ug/kg/min.
When given to patients with shock, dopamine has been well tolerated at dosages above 10 ug/kg/min. From our early experience with dopamine in 62 patients with shock of various etiologies"5 we reported a mean increase in cardiac output of 37% during dopamine given at an average infusion rate of 10,ug/kg/min (assuming the average patient weighs 78 kg). In 38 of these patients, left ventricular end-diastolic pressure (LVEDP) was measured directly and although LVEDP increased slightly from 13 to 16 mm Hg during dopamine infusion, the drug was generally well tolerated and clinical evidence of worsening ventricular function with pulmonary edema was not seen. We think it important to emphasize this difference in response to dopamine between hypotensive patients with clinical shock and normotensive patients with chronic low output cardiac failure. In the shock patient, especially when sepsis or miscellaneous factors are responsible, vascular resistance may not be elevated '6' 17 and cardiac function may be only moderately depressed. Under such circumstances, large dosages of dopamine are consistent with satisfactory ventricular performance since the adverse effect of increased afterload on ventricular function can be counterbalanced by the inotropic response to the drug coupled with restoration of arterial pressure favoring improved coronary and systemic perfusion.
On the other hand, patients with advanced heart failure not complicated by a reduction in coronary perfusion pressure frequently respond well to vasodilator therapy and are made worse by interventions causing vasoconstriction. Unlike dobutamine, the inotropic effects of dopamine are in part mediated by release of stored myocardial catecholamines,9 which may be depleted in patients with chronic heart failure.'" Therefore, although vasoconstriction may be avoided in such patients by using dopamine in low dosages, the dosage may be insufficient for achieving the desired inotropic effect and increase in cardiac output.
In contrast to dopamine, dobutamine is said to have minimal direct vascular activity even when used at higher dosages. In our patients, systemic arteriolar resistance fell in 11 (average from 21 24 have not found consistent changes in the net effect on the relationship between myocardial oxygen delivery and demand.
In summary, our study has shown that, when given in sufficient amounts, both dobutamine and dopamine can improve cardiac output in patients with chronic low output cardiac failure. Dopamine is more likely to cause persistent elevation of vascular resistance, increased left ventricular filling pressure, and clinical evidence of pulmonary congestion and edema. For these reasons, dobutamine should be favored over dopamine for increasing of cardiac output in such patients.
SUBLINGUAL NITROGLYCERIN has enjoyed longstanding and almost universal acceptance as an antianginal agent. The remarkable efficacy of this drug has led to its use not only as a therapeutic agent but also as a standard for evaluating other antianginal agents' and even as a diagnostic tool.2 Many attempts have been made to prolong the brief action of sublingual nitroglycerin by altering both molecular structure and method of administration. These attempts (peak increase 18 beats/min at 60 min), and systolic blood pressure decreased from 45 to 300 min (P < 0.005) (peak decrease 18 mm Hg at 60 min). Exercise time at 2 min after sublingual nitroglycerin increased 51% as compared to sublingual placebo (P < 0.001). After ISDN was compared to oral placebo, exercise time increased 54% at 1 hr (P < 0.005), 37% at 3 hr (P < 0.01), and 12% at 5 hr (NS). 
